Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Jan 2017
- Ended
- Dec 2023
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Omega 3 fatty acid
- Safflower seed oil
- Record updated
- 13 October 2022
- Why it stopped
- Unable to recruit participants
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Age 18-55
- Documented/ verified TBI
- Ability to swallow study agent within 48h of injury
- If a sexually active female who is able to get pregnant, must be already taking birth control (prescription contraception)
- Visual acuity/ hearing adequate for testing
- Fluency in English or Spanish
- Ability to provide informed consent for themselves
- Co-enrolled in PARC-TBI protocol (IRB protocol #825783) or TRACK-TBI (IRB protocol #825503)
- GCS 13-15
Who cannot take part
- History of pre-existing neurologic disorder, such as dementia, uncontrolled epilepsy, multiple sclerosis, strokes, brain tumors, prior severe TBI, or other disorder that confounds interpretation neuropsychological results
- Consumption of fish or seafood 3 or more times per week on average or regular administration of omega-3 supplements (e.g., cod liver oil, borage oil, fish oil or evening primrose oil) defined as an average of 250 mg/day of n-3 HUFAs, over the previous 3 months
- Use of anticoagulant medications or aspirin more than once per week within the last three months
- Enrollment in any concurrent research protocols that would interfere with participant safety or research data integrity
- Acute ischemic heart disease or abnormal heart rhythm
- History of abnormality in liver function
- History or evidence of active malignancy
- History of diabetes
- History of pre-existing disabling Axis I psychiatric disorder, such as major depression, schizophrenia, bipolar disorder or dementia
- Allergy to omega-3 fatty acid ethyl esters or any ingredient of the study agent
- Known allergy to Safflower seed oil or ragweed plants
- Allergy, hypersensitivity, or intolerance to fish oils or omega-3 fats which are found in fish
- Unstable respiratory or hemodynamic status
- Evidence of penetrating brain injury
- Requirement for craniotomy or craniectomy
- Evidence of serious infectious complications
- Pregnancy or breast-feeding
- Prisoners or patients in custody
Where in United States
- Penn Presbyterian Medical CenterPhiladelphia, United States
About the trial
What the trial wants to find out
This is a Phase 2 clinical trial designed to obtain data on relationships between potentially therapeutic doses of n-3 HUFA (highly unsaturated fatty acids) and their bioactive molecular derivatives, synaptamide, 17-hydroxy-DHA, and D-series resolvins, on clinical outcomes after TBI.
The 4 groups in the trial
- 1,000mg/day n-3 HUFATreatment being tested
Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
Treatment: Omega 3 fatty acid
- 4,000 mg/day n-3 HUFATreatment being tested
Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
Treatment: Omega 3 fatty acid
- 1 capsule safflower seed oilPlacebo, for comparison
Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
Treatment: Safflower seed oil
- 4 capsules safflower seed oilPlacebo, for comparison
Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
Treatment: Safflower seed oil
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Traumatic Brain Injury Recovery With n-3 Highly Unsaturated Fatty Acids (HUFAs): A Biomarker-driven Approach
- Record updated
- 13 October 2022